OncoMatch/Clinical Trials/NCT06700395
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
Is NCT06700395 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TQB2029 for multiple myeloma.
Treatment: TQB2029 — This is a study to evaluate the maximum tolerated dose (MTD), dose limiting toxicity (DLT), occurrence of all adverse events (AEs) and serious adverse events (SAEs), pharmacokinetic parameters, pharmacodynamic parameters, immunogenicity, and anti-tumor effects of TQB2029 for injection in Chinese adult subjects with multiple myeloma. The study is divided into Phase Ia and Ib, Phase Ia: dose escalation phase, to evaluate the safety and tolerability of TQB2029 for injection, and determining DLT and MTD; Phase Ib: Dose extension phase, to evaluate the effectiveness of TQB2029 for injection in subjects with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: Chinese patent medicines with anti-tumor indications
Subjects who have taken Chinese patent medicines with anti-tumor indications in the drug instructions that National Medical Products Administration approved within 2 weeks before the first administration.
Cannot have received: targeted therapy
Subjects who received targeted therapy ... within 3 weeks before the first medication
Cannot have received: immunotherapy
Subjects who received ... immunotherapy within 3 weeks before the first medication
Lab requirements
Blood counts
The function of main organs is normal.
Kidney function
The function of main organs is normal.
Liver function
The function of main organs is normal.
Cardiac function
The function of main organs is normal.
The function of main organs is normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify